AIM ImmunoTech (AIM) AI Stock Analysis

• Market Cap: $3.46M
• Dividend Yield: N/A
• Average Volume (3M): 149.50K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.59
• Revenue Growth: -41.05%
• EPS Growth: 57.35%
• Country: US
• Employees: 21
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -1.57
• Shares Outstanding: 3,276,425
• 10 Day Avg. Volume: 97,345
• 30 Day Avg. Volume: 149,503
• PEG Ratio: 0.01
• Price to Book (P/B): -8.47
• Price to Sales (P/S): 65.90
• P/FCF Ratio: -0.75
• Enterprise Value/Market Cap: 1.17
• Enterprise Value/Revenue: 36.05
• Enterprise Value/Gross Profit: 192.26
• Enterprise Value/Ebitda: -0.27
• 1Y Price Target: $22.00
• Price Target Upside: 1660.00% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): -3.29
• Revenue Forecast (FY): $100.00K

• Rating: 40 Underperform
• Price Target: $1.50 ▲(20.00% Upside)

The score is primarily weighed down by very weak financial performance (large losses, negative equity, and ongoing cash burn). Technicals also remain unfavorable with a broader downtrend and negative MACD, while valuation is constrained by negative earnings and no dividend support. A recent corporate update further underscored significant development and funding/regulatory risks.

Positive Factors

Clinical Progress

The ongoing DURIPANC trial with Ampligen shows promising results, indicating potential FDA approval. This progress could enhance AIM's market position in cancer treatment, driving long-term growth.

Strategic Partnerships

Partnership with AstraZeneca for combination therapy enhances AIM's credibility and access to resources, potentially accelerating product development and market entry.

Patent Protection

Securing a European patent for Ampligen strengthens AIM's intellectual property portfolio, providing a competitive edge and potential revenue from licensing or sales in European markets.

Negative Factors

Financial Instability

Negative equity indicates liabilities exceed assets, posing a risk to financial stability and limiting AIM's ability to invest in growth opportunities without external funding.

Declining Revenue

Declining revenue suggests challenges in product adoption or market penetration, impacting AIM's ability to generate sustainable cash flow and invest in R&D.

Profitability Challenges

Severe profitability issues indicate operational inefficiencies and high costs relative to revenue, which could hinder AIM's long-term financial health and growth potential.

AIM ImmunoTech Business Overview & Revenue Model

Company Description

AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. Its flagship products are Ampligen (rintatolimod), a drug of large macromolecular double-stranded ribonucleic acid molecules to treat chronic fatigue syndrome; and Alferon N Injection (Interferon alfa), a purified, natural-source, glycosylated, multi-species alpha interferon product for the treatment of genital warts. The company is also developing Ampligen for potential treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.

How the Company Makes Money

AIM ImmunoTech generates revenue through several key streams, including research grants, licensing agreements, and potential product sales. The company collaborates with academic institutions and research organizations to secure funding for its research initiatives, which contribute to its revenue. Additionally, AIM seeks to establish strategic partnerships with larger pharmaceutical companies to license its proprietary technologies and products, which can provide significant upfront payments and royalties on sales. Moreover, if any of its lead products, such as Ampligen, receive regulatory approval and enter the market, the company would earn revenues from product sales, further enhancing its financial performance.

AIM ImmunoTech Financial Statement Overview

Summary

Very weak fundamentals: large ongoing losses (net margin -140.63%), declining revenue (-7.44%), and deeply negative operating margins. Balance sheet risk is high with negative stockholders’ equity, and cash flow remains pressured with negative operating cash flow despite some improvement in free cash flow growth.

Income Statement

AIM ImmunoTech's income statement shows significant challenges with profitability. The TTM data reveals a negative net profit margin of -140.63%, indicating substantial losses relative to revenue. Revenue growth is also negative at -7.44%, suggesting declining sales. The EBIT and EBITDA margins are deeply negative, reflecting operational inefficiencies. Overall, the company faces severe profitability issues and declining revenue trends.

Balance Sheet

The balance sheet highlights financial instability with a negative stockholders' equity, leading to a negative debt-to-equity ratio. This indicates that liabilities exceed assets, a concerning sign of financial distress. The return on equity is positive due to negative equity, but this is misleading as it reflects losses rather than profitability. The equity ratio is also negative, underscoring the company's weak financial position.

Cash Flow

Cash flow analysis shows some improvement in free cash flow growth at 15.73% TTM, but the operating cash flow remains negative, indicating ongoing cash burn. The free cash flow to net income ratio is slightly above 1, suggesting that cash flow is somewhat aligned with net income, albeit both are negative. Overall, cash flow remains a concern, with limited signs of recovery.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	112.00K	170.00K	202.00K	141.00K	135.00K	163.00K
Gross Profit	21.00K	139.00K	160.00K	565.00K	-715.00K	-643.00K
EBITDA	-14.90M	-16.49M	-28.72M	-19.87M	-18.29M	-12.99M
Net Income	-15.75M	-17.32M	-28.96M	-19.45M	-19.13M	-14.40M
Balance Sheet
Total Assets	5.49M	8.61M	19.38M	40.49M	57.70M	111.02M
Cash, Cash Equivalents and Short-Term Investments	2.41M	3.98M	13.07M	34.19M	48.27M	39.00M
Total Debt	2.34M	2.94M	718.00K	837.00K	149.00K	2.29M
Total Liabilities	11.57M	9.93M	9.15M	2.02M	820.00K	49.73M
Stockholders Equity	-6.08M	-1.32M	10.23M	38.47M	56.88M	61.29M
Cash Flow
Free Cash Flow	-13.33M	-14.91M	-21.85M	-16.38M	-14.60M	-10.96M
Operating Cash Flow	-12.93M	-14.89M	-21.27M	-16.11M	-13.96M	-10.37M
Investing Cash Flow	5.65M	4.71M	-832.00K	10.99M	-631.00K	-9.16M
Financing Cash Flow	8.71M	6.44M	485.00K	80.00K	8.19M	56.56M

AIM ImmunoTech Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.25
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AIM, the sentiment is Negative. The current price of 1.25 is above the 20-day moving average (MA) of 1.23, below the 50-day MA of 1.32, and below the 200-day MA of 4.15, indicating a bearish trend. The MACD of -0.06 indicates Positive momentum. The RSI at 35.45 is Neutral, neither overbought nor oversold. The STOCH value of 27.69 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AIM.

AIM ImmunoTech Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
APLM	52 Neutral	$21.49M	-0.69	-380.13%	―	―	54.41%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
PCSA	41 Neutral	$5.39M	-0.07	-270.74%	―	―	72.88%
AIM	40 Underperform	$3.46M	-0.05	―	―	-41.05%	57.35%
GTBP	40 Underperform	$14.04M	-0.15	-356.99%	―	―	54.62%

AIM ImmunoTech Corporate Events

AIM ImmunoTech Adjusts Class E Warrant Terms After Dividend

On January 20, 2026, AIM ImmunoTech notified holders of its Class E common stock purchase warrants of changes triggered by a stock dividend issued on January 13, 2026, in which shareholders received one share of common stock for every 1,000 shares outstanding as of January 9, 2026, and one share for every outstanding option or warrant entitled to stock dividends. The stock dividend constituted a Share Combination Event that, under the warrant terms, required an adjustment: during the defined evaluation period the volume-weighted average price fell below the floor price, leading the company to reduce the Class E warrant exercise price to $1.439 per share and inversely increase the number of outstanding Class E warrants to 5,561,125, while confirming that this pricing floor prevents further similar adjustments under the same provision going forward.

The most recent analyst rating on (AIM) stock is a Sell with a $1.00 price target. To see the full list of analyst forecasts on AIM ImmunoTech stock, see the AIM Stock Forecast page.

AIM ImmunoTech Highlights Ampligen Development Risks and Plans

In January 2026, AIM ImmunoTech furnished a corporate presentation outlining its ongoing and planned activities to evaluate Ampligen as a treatment for a range of viral diseases, cancers and immune-deficiency disorders, while emphasizing that the material is being provided for informational purposes rather than as a formal, liability-bearing filing. The company underscored that Ampligen remains in early-stage development with significant additional animal and human testing required, and cautioned investors about substantial risks, including the possibility of unsuccessful or inconclusive clinical trials, regulatory and funding uncertainties, and operational challenges associated with conducting studies and protecting intellectual property in foreign markets.

The most recent analyst rating on (AIM) stock is a Buy with a $22.00 price target. To see the full list of analyst forecasts on AIM ImmunoTech stock, see the AIM Stock Forecast page.

AIM ImmunoTech Completes 2025 Annual Stockholder Meeting

On December 16, 2025, AIM ImmunoTech held its 2025 Annual Meeting of Stockholders, during which essential governance matters were voted on. Key outcomes included the election of directors, approval of the company’s independent accounting firm, shareholder approval for executive compensation on an advisory basis despite not meeting required majority voting power, and the decision to hold annual advisory votes on executive compensation.

The most recent analyst rating on (AIM) stock is a Sell with a $1.50 price target. To see the full list of analyst forecasts on AIM ImmunoTech stock, see the AIM Stock Forecast page.

AIM ImmunoTech Enters Note Purchase Agreement

On November 18, 2025, AIM ImmunoTech Inc. entered into a Note Purchase Agreement with Streeterville Capital, LLC, resulting in the sale of an unsecured Promissory Note with a principal amount of $3,301,250. The transaction, which closed on the same date, involved a purchase price of $2,500,000 after accounting for an issuance discount and transaction costs. The Note bears a 10% annual interest rate, with a maturity date set for 24 months from issuance. The agreement includes mandatory prepayment terms tied to future fundraising activities and outlines conditions for default, which could lead to increased interest rates.

The most recent analyst rating on (AIM) stock is a Sell with a $1.50 price target. To see the full list of analyst forecasts on AIM ImmunoTech stock, see the AIM Stock Forecast page.